Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  Alpha Arbutin
Research reference — not for sale

Alpha Arbutin

B
lead outcome
Hyperpigmentation / dark spots (appearance)
grades vary by outcome ↓
Small molecule (non-peptide)
also called — α-arbutin · alpha-arbutin · 4-hydroxyphenyl-α-D-glucopyranoside · INCI: Alpha-Arbutin
skin appearance (cosmetic)hyperpigmentation appearanceeven tone / brighteninggentle brightener
In brief

Alpha arbutin is a biosynthesised glycoside — hydroquinone bound to glucose — used as a gentle, stable brightening active. It works by competitive tyrosinase inhibition, slowing melanin synthesis without destroying pigment cells, and — importantly — at cosmetic concentrations it does NOT release free hydroquinone in skin, so it avoids hydroquinone's cytotoxicity, ochronosis, and rebound. The EU's safety committee recognises up to 2% on the face as safe. It is graded B at the softer end: the mechanism is well grounded and human data is accumulating — a 2024 split-face pilot found a 5% alpha-arbutin plus 2% kojic cream comparable to a prescription triple-combination cream for melasma with lower recurrence — but the strongest human trials are combinations, so isolated standalone evidence is thinner. A sensible, gentle starting point among brighteners, best read as promising rather than fully settled.

Legal standing, by region
International
Lawful cosmetic ingredient

Alpha arbutin is a lawful cosmetic brightening ingredient globally, including the EU (Regulation (EC) 1223/2009). The EU's Scientific Committee on Consumer Safety (SCCS) recognises up to 2% on the face (and 0.5% on the body) as safe. Products and studies typically use around 1–5%. Not a restricted substance.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Hyperpigmentation / dark spots (appearance)
Gentle and gradual; daily sun protection essential
Competitive tyrosinase inhibition (Boo 2021 mechanistic review); Sugimoto 2004 three-dimensional human-skin model reporting melanin reduced to roughly 40% of control · Gradual fading of dark spots and uneven tone
B
Post-inflammatory hyperpigmentation / PIH (appearance)
Most human data comes from combination products, not arbutin alone
Consistent tyrosinase mechanism plus accumulating human data · Softening of post-inflammatory marks
B
Melasma (appearance, usually in combination)
A combination result (arbutin plus kojic), not arbutin alone; a single small pilot
Tantanasrigul 2024 split-face, evaluator-blinded randomized pilot — a 5% alpha-arbutin + 2% kojic acid cream comparable to a prescription triple-combination cream over 12 weeks, with lower recurrence after stopping · Comparable melasma improvement to a prescription combination in one pilot
B
Isolated standalone efficacy (arbutin alone vs control)
Hard to isolate arbutin's own contribution from its formulation partners
Most human trials are combinations; standalone clinical data is thinner · Promising rather than fully settled
C
Gentleness & safety (no free hydroquinone at cosmetic concentration)
A recognised advantage, not an efficacy grade; patch test a new product
EU-SCCS recognises up to 2% on the face as safe; non-cytotoxic at cosmetic strengths, with no hydroquinone-type ochronosis or rebound reported · A gentle, well-tolerated entry point among brighteners
Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • for the appearance of a more even, brighter-looking complexion
  • helps reduce the look of dark spots
  • gentle brightening support for sensitive skin
  • for a more uniform-looking tone
✕ Not allowed (medicinal)
  • bleaches skin
  • releases hydroquinone
  • as effective as hydroquinone
  • treats melasma
  • cures hyperpigmentation
  • inhibits tyrosinase
  • skin-whitening

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

The honest part

Alpha arbutin is chemically hydroquinone bound to glucose, but at cosmetic concentrations it does NOT release free hydroquinone in skin — so it is not a hydroquinone substitute in potency, and the comparison should not be read as hydroquinone-level strength. It is a gentle, gradual brightener; persistent or clearly hormonal pigmentation such as melasma is a dermatologist's territory, and daily broad-spectrum sunscreen is essential with any pigment active.

Identity

a biosynthesised glycoside — a molecule of hydroquinone bound to glucose — that is far more stable and effective than the naturally occurring beta-arbutin. Crucially, despite that hydroquinone backbone, at cosmetic concentrations it does not release free hydroquinone in skin, so it sidesteps hydroquinone's cytotoxicity and rebound risks. It is one of the most widely used brightening actives in modern formulation; the EU's safety committee recognises up to 2% on the face as safe. For the full readable explanation of what it is and how it works, see the companion guide, what is alpha arbutin?

Development & history

  • Derived from the plant molecule arbutin, but produced as the more stable synthetic alpha isomer by enzymatic biosynthesis (roughly ten times more effective at inhibiting tyrosinase than the natural beta form, and considerably more stable).
  • Adopted through the 2000s–2010s as a mainstream, formulator-friendly brightening active.
  • Formally recognised by the EU-SCCS at up to 2% on the face; increasingly studied in human trials, usually in combination with other actives.

Mechanism (as proposed)

a competitive inhibitor of tyrosinase — the copper-containing enzyme controlling the rate-limiting step of melanin production. Because its structure resembles tyrosine (the enzyme's natural substrate), it occupies the active site and slows melanin synthesis without destroying pigment cells — a "brake, not bleach" action that is the source of its gentleness. In-vitro and ex-vivo work consistently shows this inhibition, with a three-dimensional human-skin-model study reporting melanin dropping to roughly 40% of control. The honest gap, as with most brighteners, is between a clean lab result and the more modest, gradual effect on intact skin.

Related reading

Sources — 3 cited
01Tantanasrigul P, Sripha A, Chongmelaxme B. The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma: A Split-Face, Evaluator-Blinded Randomized Pilot Study. J Cosmet Dermatol. 2024;e16562.
02Sugimoto K, Nishimura T, Nomura K, Sugimoto K, Kuriki T. Inhibitory Effects of Alpha-Arbutin on Melanin Synthesis in Cultured Human Melanoma Cells and a Three-Dimensional Human Skin Model. Biol Pharm Bull. 2004;27(4):510-514.
03Boo YC. Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties. Antioxidants (Basel). 2021;10(7):1129.
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated 2026-07-12.

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
Kojic AcidC
Small molecule (non-peptide)
Niacinamide (Vitamin B3)A
Small molecule (non-peptide)
Vitamin C (L-Ascorbic Acid)A
Small molecule (non-peptide)
Azelaic AcidB
Small molecule (non-peptide)
Tranexamic AcidB
Small molecule (non-peptide)
Explore by goal
Skin & aesthetic
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we grade
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

Alpha Arbutin — evidence, uses & status · Vallydia